scholarly journals Phase II Study of Sorafenib and Bortezomib for First‐Line Treatment of Metastatic or Unresectable Renal Cell Carcinoma

2015 ◽  
Vol 20 (4) ◽  
pp. 370-371 ◽  
Author(s):  
Arpit Rao ◽  
Richard Lauer
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma

Cancer ◽  
2011 ◽  
Vol 118 (5) ◽  
pp. 1252-1259 ◽  
Author(s):  
Carlos H. Barrios ◽  
David Hernandez-Barajas ◽  
Michael P. Brown ◽  
Se-Hoon Lee ◽  
Luis Fein ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Line Treatment ◽  
First Line ◽  
Once Daily ◽  
First Line Treatment

scholarly journals Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Cancer ◽  
2020 ◽  
Vol 126 (24) ◽  
pp. 5247-5255 ◽  
Author(s):  
Darren R. Feldman ◽  
Yasser Ged ◽  
Chung‐Han Lee ◽  
Andrea Knezevic ◽  
Ana M. Molina ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Renal Cell ◽  
Phase Ii Trial ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document